Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and ...

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Life Insurance Corporation of India’s stake in Dr. Reddy’s Laboratories raced past the 8% mark recently with the country’s ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.